A new analysis has found that the anti-aging supplement called nicotinamide mononucleotide (NMN) produced a small drop in the lower number of blood pressure readings in human trials.
That result keeps NMN under clinical consideration, while more effective strategies continue to produce far larger and more consistent reductions in blood pressure.
Evidence lands softly
Across ten small human trials with 11 comparison arms, the signal emerged in adults whose blood pressure was already beginning to rise.
Researchers at Hangzhou Normal University in eastern China (HZNU) tied NMN to that measurable change when they compared supplement groups with inactive comparison groups.
The effect held on the lower reading during heart relaxation, but the upper reading during each heartbeat did not fall clearly across the full group.
That narrow split gave NMN a measurable result without yet giving it the weight of a full treatment claim.
Supplement targets cells
Inside cells, nicotinamide mononucleotide – the compound called NMN – sits upstream of a molecule cells use every day called NAD+.
That molecule, NAD+, helps cells turn food into usable energy and repair damaged genetic material after daily cellular stress.
Levels often decline with age, so companies sell NMN as a way to refill that cellular supply.
Raising a blood marker, however, does not prove that arteries, hearts, or lives will improve during normal health.
Pressure points matter
Such a small drop can be hard to interpret because ordinary readings often change between measurements.
Worldwide, a 2025 World Health Organization report estimated 1.4 billion adults ages 30-79 had high blood pressure, giving small average changes real scale.
For an individual considering a supplement, that small change may not alter a doctor’s plan or lead to medication changes.
That gap between population-level averages and individual outcomes explains why the result calls for careful restraint in real-world decisions.
Older adults stood out
Among adults age 60 and older, the top blood pressure number showed a slightly larger drop in the review.
Aging can stiffen arteries, so any mild vessel relaxation could show more strongly in systolic readings.
Evidence from that older group came from a smaller slice of data, not a large dedicated trial. Without longer testing, the age finding remains a clue rather than a reason to prescribe NMN.
Evidence stays narrow
Trial designs kept the answer narrow because most studies lasted only four to 12 weeks.
Short follow-up can catch early pressure changes, but it cannot reveal heart attacks or strokes prevented over time.
Participants mostly had early pressure elevation, and no trial enrolled moderate or severe high blood pressure.
That profile makes the result most relevant to prevention, not advanced disease or urgent treatment.
Lifestyle still leads
Established habits, including Dietary Approaches to Stop Hypertension (DASH), still beat NMN by larger margins.
In a major trial, the DASH diet lowered the top blood pressure number by a noticeably larger amount than a typical diet.
Regular aerobic exercise also produced clear reductions in that top number across dozens of clinical trials.
Clinical guidelines still place DASH eating, movement, weight management, and lower sodium ahead of supplements for pressure control.
Experts urge restraint
Outside experts treated the finding as useful but not powerful enough to replace proven care from the start.
“NMN supplementation is an intriguing area of research because it targets NAD+ metabolism and cellular aging pathways,” said Lauri Wright, Ph.D., RDN, director of nutrition programs and associate professor at the University of South Florida College of Public Health.
Wright said the current evidence points to only small improvements in blood pressure and emphasized the need for further research.
Wright’s caution matches the data because blood pressure was often a side measure, not the main question from the start.
Supplement labels overpromise
Store shelves can turn a small trial signal into a promise the evidence has not earned.
Dietary supplements do not get Food and Drug Administration approval for safety or effectiveness before sale, though they are sold to add nutrients or compounds.
Trials tested 250 to 1,500 mg daily, but they did not establish a best dose for years-long use.
Regulatory gaps matter because blood pressure claims can lead people to delay care that already works in time.
Patients need context
People taking pressure medicine need extra caution because even small drops can stack with prescribed drugs.
A clinician can check home readings, medication timing, kidney health, and other reasons pressure rises before suggesting changes.
Adults with normal readings have less room to benefit, so the same pill may offer no measurable gain.
Until stronger trials arrive, medical advice should follow risk, age, current readings, and personal health history, not marketing pressure.
Next trials matter
New evidence draws a clear line: NMN may nudge pressure downward, but it has not proved heart protection for now.
Future trials need more people, longer follow-up, and actual heart attack or stroke data before the supplement earns a clinical role.
The study is published in Nutrients.
—–
Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates.
Check us out on EarthSnap , a free app brought to you by Eric Ralls and Earth.com.
—–